NasdaqGM:TNGXBiotechs
Tango Therapeutics (TNGX) Q4 Revenue Collapse To US$0 Reinforces Bearish Volatility Narrative
Tango Therapeutics (TNGX) has put out a mixed set of FY 2025 numbers, with Q4 revenue at US$0 million and basic EPS at a loss of US$0.29 per share, against a trailing twelve month basic EPS loss of US$0.87 on revenue of US$62.4 million. Over recent quarters, the company has seen revenue move between US$3.2 million and US$53.8 million while basic EPS has swung from a profit of US$0.14 back to quarterly losses of around US$0.35. This has left margins firmly in loss making territory and put the...